Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 TS ID 10767Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg TS ID 11894Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemicStatus:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC